# Indivior Pharmaceuticals

Type: Company (INDV)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/indivior-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/indivior-pharmaceuticals

## Timeline

- **2026-10**: Expected Deal Close — The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.
- **2026-08-03**: Merger and Earnings Announcement — Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.

## Recent coverage (1 stories)

### Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target
2026-08-04 00:21:58 · Sentiment: Bullish · Impact: 6/10 · Sources: 4

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
Full story: https://gethealthbrief.com/story/supernus-indivior-cns-merger-125m-synergy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.